알파-3 베타-4 니코틴 수용체

Alpha-3 beta-4 nicotinic receptor

알파-3 베타-4 니코틴 수용체는 α3β4 수용체와 갱리온형 니코틴 수용체로도 알려져 있으며,[1] 니코틴성 아세틸콜린 수용체의 일종으로 α3과 β4 서브유닛으로 구성되어 있다.[2][3]주로 Na와+ K+ 투과성 증가에 의해 활성화로 전후 및/또는 사전 시냅스 흥분 현상이 발생하는 자율성 갱년기와[4] 부신성 망막에 위치한다.[5][3]

다른 니코틴성 아세틸콜린 수용체와 마찬가지로 α3β4 수용체는 펜트아메리카 [(α3)(mβ4)n 여기서 m + n = 5]이다.정확한 서브유닛 스토이치측정법은 알려져 있지 않으며, 다양한 서브유닛 스토이치측정법으로 생체내 하나 이상의 기능성 α3β4 수용체 조립이 가능하다.

α3β4 수용체를 억제하는 리간드는 약물추구 행동을 조절하는 것으로 나타나 α3β4가 새로운 중독성 방지제 개발의 유망한 대상이 되고 있다.

리간즈

고민자

반목자

경쟁력

"compound 5"(Zaveri 2010)의 3d 구조Ki, αβ34 nAChR에서 508nM

비경쟁력

참고 항목

참조

  1. ^ 약리학, (랑, 데일, 리터 & 무어, ISBN0-443-07145-4, 5부, 처칠 리빙스톤 2003) 페이지 138.
  2. ^ Stauderman KA, Mahaffy LS, Akong M, Veliçelebi G, Chavez-Noriega LE, Crona JH, Johnson EC, Elliott KJ, Gillespie A, Reid RT, Adams P, Harpold MM, Corey-Naeve J (February 1998). "Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha2beta4, alpha3beta4 and alpha4beta4 stably expressed in HEK293 cells". The Journal of Pharmacology and Experimental Therapeutics. 284 (2): 777–89. PMID 9454827.
  3. ^ a b Xiao Y, Kellar KJ (July 2004). "The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells". The Journal of Pharmacology and Experimental Therapeutics. 310 (1): 98–107. doi:10.1124/jpet.104.066787. PMID 15016836. S2CID 23900581.
  4. ^ Poth K, Nutter TJ, Cuevas J, Parker MJ, Adams DJ, Luetje CW (January 1997). "Heterogeneity of nicotinic receptor class and subunit mRNA expression among individual parasympathetic neurons from rat intracardiac ganglia". The Journal of Neuroscience. US National Library of Medicine. 17 (2): 586–96. doi:10.1523/JNEUROSCI.17-02-00586.1997. PMC 6573231. PMID 8987781.
  5. ^ Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, Moretti M, Pedrazzi P, Pucci L, Zoli M (October 2009). "Structural and functional diversity of native brain neuronal nicotinic receptors" (PDF). Biochemical Pharmacology. US National Library of Medicine. 78 (7): 703–11. doi:10.1016/j.bcp.2009.05.024. PMID 19481063.
  6. ^ a b c d e f g h i Xiao Y, Meyer EL, Thompson JM, Surin A, Wroblewski J, Kellar KJ (August 1998). "Rat alpha3/beta4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function". Molecular Pharmacology. 54 (2): 322–33. doi:10.1124/mol.54.2.322. PMID 9687574.
  7. ^ Matera C, Quadri M, Sciaccaluga M, Pomè DY, Fasoli F, De Amici M, Fucile S, Gotti C, Dallanoce C, Grazioso G (January 2016). "Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the α3β4 nicotinic acetylcholine receptor subtype". European Journal of Medicinal Chemistry. 108: 392–405. doi:10.1016/j.ejmech.2015.11.045. PMID 26706350.
  8. ^ Prado WA, Segalla DK (2004). "Antinociceptive effects of bethanechol or dimethylphenylpiperazinium in models of phasic or incisional pain in rats". Brain Res. 1018 (2): 272–82. doi:10.1016/j.brainres.2004.05.085. PMID 15276888. S2CID 45145197.
  9. ^ Rang, H. P. (2003), Pharmacology, Edinburgh: Churchill Livingstone, ISBN 0-443-07145-4 149페이지
  10. ^ Bencherif M, Schmitt JD, Bhatti BS, Crooks P, Caldwell WS, Lovette ME, Fowler K, Reeves L, Lippiello PM (March 1998). "The heterocyclic substituted pyridine derivative (+/-)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors". The Journal of Pharmacology and Experimental Therapeutics. 284 (3): 886–94. PMID 9495846.
  11. ^ "SR 16584 (CAS 1150153-86-8)". R&D Systems. Retrieved 3 December 2017.
  12. ^ Zaveri, NT (2011). "The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications". Current Topics in Medicinal Chemistry. 11 (9): 1151–6. doi:10.2174/156802611795371341. PMC 3899399. PMID 21050175.
  13. ^ a b Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ (June 2000). "Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors". The Journal of Pharmacology and Experimental Therapeutics. 293 (3): 962–7. PMID 10869398.
  14. ^ a b Damaj MI, Flood P, Ho KK, May EL, Martin BR (February 2005). "Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity". The Journal of Pharmacology and Experimental Therapeutics. 312 (2): 780–5. doi:10.1124/jpet.104.075093. PMID 15356218. S2CID 149958.
  15. ^ a b c Xiao, Yingxian; Smith, Richard D.; Caruso, Frank S.; Kellar, Kenneth J. (October 2001). "Blockade of Rat α3β4 Nicotinic Receptor Function by Methadone, Its Metabolites, and Structural Analogs — JPET". Journal of Pharmacology and Experimental Therapeutics. 299 (1): 366–371.
  16. ^ Arias HR, Targowska-Duda KM, Feuerbach D, Sullivan CJ, Maciejewski R, Jozwiak K (March 2010). "Different interaction between tricyclic antidepressants and mecamylamine with the human alpha3beta4 nicotinic acetylcholine receptor ion channel". Neurochemistry International. 56 (4): 642–9. doi:10.1016/j.neuint.2010.01.011. PMID 20117161. S2CID 29461221.
  17. ^ Miller DK, Wong EH, Chesnut MD, Dwoskin LP (August 2002). "Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors". The Journal of Pharmacology and Experimental Therapeutics. 302 (2): 687–95. doi:10.1124/jpet.302.2.687. PMID 12130733.
  18. ^ Toll L, Zaveri NT, Polgar WE, Jiang F, Khroyan TV, Zhou W, Xie XS, Stauber GB, Costello MR, Leslie FM (May 2012). "AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats". Neuropsychopharmacology. 37 (6): 1367–76. doi:10.1038/npp.2011.322. PMC 3327842. PMID 22278092.
  19. ^ González-Rubioa JM, Rojoa J, Tapiaa L, Maneud V, Muletc J, Valorc LM, Criadoc M, Salac F, García AG, Gandía L (2004). "Choline as a tool to evaluate nicotinic receptor function in chromaffin cells" (PDF). In Borges R, Gandía L (eds.). Cell Biology of the Chromaffin Cell. Spain: Instituto Teófilo Hernando.